Wenn Sun, Ph.D.
Wenn has over 20 years of business development and alliance management experience in academia and the pharmaceutical industry. Wenn set up and managed the first industry liaison function at the Lurie Comprehensive Cancer Center at Northwestern University. She also built and managed the Science Management function at the Genome Institute of Singapore. In 2003, in collaboration with the National Comprehensive Cancer Network (NCCN), she helped introduce NCCN Guidelines to China, which are now widely distributed. Wenn served as Director of Strategic Alliance and Business Development at NexMed between 2003 and 2005. From 2006 to 2010, Wenn led the strategic alliance function at GlaxoSmithKline Oncology, and established global partnerships in clinical research, including six major oncology networks.
David Kerr, CBE MA MD DSc FRCP FMedSci
David is a researcher of cancer medicine at the University of Oxford in the U.K., and is an internationally recognized researcher in colorectal cancer care and research. David has published over 300 papers and authored over 20 books. He has also been awarded four prestigious, international research prizes, including the NHS's first Nye Bevan award for innovation. David is considered a thought leader in healthcare policy and served as Health Advisor to Prime Ministers David Cameron and Tony Blair in the U.K.
Debasish Roychowdhury, MD
Debasish has over 20 years of comprehensive pharmaceutical industry and senior management experience. He has a deep expertise in drug development and in particular, clinical development and regulatory affairs. He has successfully led product development teams resulting in approvals of six new molecular entities and numerous supplemental indications throughout the world, in the field of oncology, hematology and supportive care. After serving five years as a faculty member at the University of Cincinnati, Debasish joined Eli Lilly in 1999, GlaxoSmithKline in 2005, and Sanofi-Aventis in 2009 where he served until December 2013, as Senior Vice President Global Oncology, and a Member of the Management Committee.
Jeff Thomis, Ph.D.
Jeff played a major part in the successful development and registration of eight commercially successful products in the fields of cardiovascular and infectious diseases at Bristol-Myers-Squibb. He was also instrumental in establishing one of the first clinical research centers for a U.S.-based company, conducting mainly IND studies in Europe. Jeff was most recently President of Clinical Development at Quintiles, and managed its unprecedented growth in Europe, including unlocking the potential of Eastern Europe for clinical research. Jeff currently serves as the Chairman of Idis Pharma, a company providing medicines for patients with unmet medical needs, and as a senior advisor to NovaQuest, a health care investment company.
Vivian has over 20 years of broad-range experience in finance, operations, out-licensing and M&A transactions in the pharmaceutical industry. In 1995, Vivian co-founded NexMed, Inc., (renamed Apricus Biosciences Inc., Nasdaq: APRI). During her 15-year tenure at NexMed/Apricus Bio, Vivian served in various executive positions, including as its Chairman of the Board, Chief Executive Officer and Chief Financial Officer. Vivian served as Chief Executive Officer of Innovus Pharmaceuticals, Inc., a start-up company, from 2011 to 2013.